Discovery and validation of biomarkers has traditionally required the use of tissue for analysis of RNA, DNA or protein. This has been especially true for RNA based biomarkers, because RNase degradation of free RNA makes translation of tissue based biomarkers into blood based tests highly problematic. However, the discovery that exosomes found in biofluids contain stable, disease specific RNA, represents a potential paradigm shift for biomarker discovery and development. Exosome RNA can be used to monitor tumor derived mutations in biofluids, but can also be used to monitor RNA levels reflective of different signaling pathways (including mRNA, miRNA, lncRNA and others). In addition, exosome RNA can be used to monitor cell activities resulting in fusions and RNA splice variants that cannot be measured on circulating free tumor DNA.
In the first half of this webinar, Dr Skog will discuss the exosome composition, different sources of RNA in biofluids and approaches to isolate them. Following this overview, he will talk about clinical applications of exosome biomarkers.
Dr. Johan Skog, Chief Scientific Officer and Founding Scientist, Exosome Diagnostics
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden
Who Should Attend?
MicroRNA service providers, CROs, academics, plus –
Researchers in the fields of:
- Biomarker Discovery
- Gene Expression
- MicroRNA Discovery
Whether your passion for answers takes you to a laboratory bench or a hospital bedside, the pursuit often begins with a blood or tissue sample. The deepest mysteries of disease and other biological processes – the answers you seek – are encoded in the building blocks of life, DNA.
Yet the work of learning what these molecules can tell you is quite a journey, and we at QIAGEN understand the challenges associated with this quest.
Our commitment is to enable you, like more than 500,000 customers around the world, to quickly and reliably reach your goal of useful, actionable insights. To this end, QIAGEN offers you innovative solutions that cover every single step along this journey – not just technologies, but bridges from samples to insights. As you advance to new frontiers, QIAGEN also advances – and this website’s updated look and feel reflects our end-to-end commitment to your journey.
Sample to Insight means QIAGEN offers you the industry’s most reliable sample technologies, because samples matter to your success. Our top-quality assays and panels enable you to accurately analyze and identify diseases and genetic variations. Our bioinformatics software and curated knowledge bases transform your raw data into relevant, actionable findings. And our automation solutions provide you seamless and cost-effective workflows. Sample to Insight.
The insights you gain may lead to one small step or a giant leap forward for science and healthcare. Partnering with QIAGEN, your work can make a difference!